917813-60-6
Chemical Structure
FLLL12
Synonym(s): GO-Y026
- CAS No.: 917813-60-6
- Formula:C21H22O7
- Molecular Weight:386.40
InChIKey: DDGVRFAFSCAHHH-KQQUZDAGSA-N
SMILES: COC(C=C1/C=C/C(/C=C/C2=CC(OC)=C(C(OC)=C2)O)=O)=C(C(OC)=C1)O
Biological Activity: FLLL12 (GO-Y026) is a curcumin analog anticancer agent. FLLL12 inhibits the phosphorylation of AKT, Bcl-2, Bid, EGFR, mTOR, FOXO1a, FOXO3a, STAT3, HER2/neu, as well as pancreatic AKT/STAT3; upregulates the expression of Bim and DR5; and activates PTPs. FLLL12 regulates downstream pathways, induces mitochondria-mediated and DR5-dependent extrinsic apoptosis, inhibits cancer cell viability, proliferation, anchorage-independent growth and migration, and exerts a synergistic effect with Doxorubicin (HY-15142A). FLLL12 can be used in research related to head and neck squamous cell carcinoma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, colon cancer and colorectal cancer[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FLLL12 | FLLL12 (GO-Y026) is a curcumin analog anticancer agent. FLLL12 inhibits the phosphorylation of AKT, Bcl-2, Bid, EGFR, mTOR, FOXO1a, FOXO3a, STAT3, HER2/neu, as well as pancreatic AKT/STAT3; upregulates the expression of Bim and DR5; and activates PTPs. FLLL12 regulates downstream pathways, induces mitochondria-mediated and DR5-dependent extrinsic apoptosis, inhibits cancer cell viability, proliferation, anchorage-independent growth and migration, and exerts a synergistic effect with Doxorubicin (HY-15142A). FLLL12 can be used in research related to head and neck squamous cell carcinoma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, colon cancer and colorectal cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Yamakoshi H, et al. Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof. Bioorganic & medicinal chemistry. 2010 Feb;18(3):1083-92. [Content Brief]
- [2]. Lin L, et al. New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci. 2009;100(9):1719-1727.
- [3]. Friedman L, et al. Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. Anti-cancer drugs. 2009 Jul;20(6):444-9. [Content Brief]
- [4]. Cen L, et al. New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells. BMC cancer. 2009 Mar 30;9:99. [Content Brief]
- [5]. Haque A er al. FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway. Cancer Lett. 2015 Jul 28;363(2):166-75.
- [6]. Anisuzzaman AS, et al. Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers. Cancer prevention research (Philadelphia, Pa.). 2016 Jan;9(1):63-73. [Content Brief]
Keywords
